This cine imaging incurs no additional radiation exposure. Although some conventional systems acquire planar imaging during treatment, the radiation dose over a large area would be excessive to achieve the continuous monitoring of the MR-linac. Second, while using external surrogates facilitates continuous monitoring, these surrogates require at least an additional 1 mm margin to ensure correlation with the tumor. 5 Third, the precise gating window of the MRlinac provided by its continuous tumor tracking limits or eradicates multileaf collimator (MLC) interplay issues, which was reported to affect delivery accuracy of other modalities 6 and thus reduce target coverage. 7 Lastly, the tumor based gating eliminates the need to define an internal target volume (ITV), which is conventionally used to ensure tumor coverage during the breathing cycle, but increases the volume of normal lung irradiated. Further, traditional ITVs are just a snapshot of tumor motion observed over tens of seconds in a 4D CT. When compared to a treatment length cine-MRI based ITV, the four-dimensional computed tomography (4D CT) based ITV typically captures only 45%-90% of the required volume, 8 leading to potential under dosing. The MR-linac continuous tracking accounts for the breathing motion including large excursions of the tumor, so that this motion does not have to be forcibly limited.
With the above-mentioned target monitoring and tracking, immobilization for MR-linacs does not then feature compression or breath control, leading to higher patient comfort during treatment. Due to the continuous imaging of the tumor, the patient can be coached by the therapists during treatment, or even see and respond to their own cine-MRI, in order to achieve optimal breath holds. By consistently placing the tumor in the gating window, the gating duty cycle
Observed changes in tumor volume coupled with tumor response data can inform dose adaption, to provide the optimal curative dose.
As MR-linacs become more prevalent, these advantages will be borne out in improved outcomes for our lung SBRT patients. The couch correction range is also limited with no option of couch rotation and, in some models, lateral translation. Furthermore, the electron return effect is much more pronounced in lung and can lead to considerable dose distortion at tissue-air interfaces. Some early studies have shown increased dose in lung and skin, as well as compromises to the accuracy of both patient plan and QA dosimetry.
11,22,23
2.B.2 | Technical limitations of the MR component
The most desirable features to those early adopters might be the real-time internal imaging capability with an MR scanner. However, cautions should be taken as they are not standard diagnostic MR scanners either. First, the MR-linac often uses lower magnetic field strengths than diagnostic MRIs (e.g., ViewRay MRIdian uses a 0.35 T scanner), therefore rendering compromised MR image quality. Second, the limited real-time tracking range excludes those cases with very peripheral lesions. Third, real-time target monitoring is based on 2D MR cine images, therefore omitting the volumetric or the thirddimension motion information. Fourth, the MR sequences typically used for lung are prone to irregular breathing artifacts and banding artifacts. 24 Fifth, in the desirable adaptive radiotherapy application, MRI cannot provide the CT-number information for heterogeneity correction which is especially important for lung SBRT dose calculation. Any method to address this fundamental limitation introduces additional uncertainties which are more pronounced for lung because lung and bone feature little MR signal. 25 Last but not least, tissue heterogeneity in lung can induce pronounced geometric distortions in MR images due to local susceptibility differences, and these errors are in addition to other MR distortions such as those due to main magnetic field and gradient field nonlinearity. 26 
2.B.3 | Incompatible patient populations
For the patient population with any contraindication against MRI, the MR-linac is not an option. These include patients with claustrophobia and those with ferromagnetic implants such as prostheses, cardiac pacemakers and defibrillators, artificial heart valves, and cochlea implants. In addition, due to the bore size limitation, the MR-linac also excludes large patients and prevents the use of many immobilization devices and body positions.
2.B.4 | Alternative modalities
Currently, there are many successful alternative modalities and technologies for lung SBRT that the MR-linac cannot rival. As mentioned previously, standard linacs are capable of delivering highly conformal lung SBRT plans at very high speeds with VMAT and high dose rates. 19 Whereas the excess cost may not be justified for lung SBRT where the standard treatment modalities are much more cost-effective and highly successful with >90% local control rates and low toxicity to normal tissues, along with adequate image-guidance and tracking. 27, 28 In conclusion, MR-linac is clearly not a viable lung SBRT treatment modality for a large population of patients with contraindications. For the other patients, it is still not the best modality based on the arguments above, as the alternative modalities provide more advanced dosimetry and delivery efficiency, more robust and versatile image guidance and motion management approaches, clear costeffectiveness, and well-documented clinical success. While there are increased MU for off-axis MR-linac treatments, the double stack MLC means there is no increase in leakage radiation.
The article cited 21 in fact finds no other issues with off-axis treatment. In terms of aligning the patient after imaging, commercial MRlinacs either shift the couch or shift the MLC and rotational corrections are not dosimetrically important for lung SBRT. 29 Electron return effect is accounted for in the Monte Carlo dose planning and there is only an increase for skin in standard fractionation, not SBRT. 22 The article however confirms lung dose is lowered due to More importantly, while the MR-linac should be further advanced as a frontrunner modality toward that vision for diseases like pancreatic cancer, it is not the case for lung SBRT. For pancreas, current radiotherapy provides relatively poor efficacy with organ toxicity partly due to low soft-tissue imaging contrast, while MRI may offer the important soft-tissue contrast resolution that is superior to the competing x-ray technologies. Whereas for lung, contrast is not as challenging, and current SBRT can already achieve 98% tumor control as cited by Dr. Godley. 4 As discussed above and will be stressed again below, numerous existing technical issues in MR-linacs make it far from being the ultimate solution toward that vision. But even hypothetically assuming all issues would have been perfectly resolved someday, arguing for the MR-linac as the best modality for lung SBRT would still be like arguing for proton therapy for prostate: Are there enough clinically meaningful gains to justify the higher cost?
Let's revisit MR-linacs' three main advantages laid out by Dr.
Godley.
3.B.1 | Comfort
With VMAT, high dose rates and fast collimators, lung SBRT treat- Meanwhile, standard linacs also have developed solutions such as MLC-tracking and couch-tracking, 35, 36 but these solutions would be difficult to adopt on MR-linacs due to the interfering magnetic field.
The so-called "MR-tracking" is not really "tracking" but gating, which substantially lengthens the treatment duration and has fallen out of fashion for lung SBRT because of it. In fact, the MR-gating may actually be managing the extra motion uncertainty created by the lengthened treatment but does not necessarily improve the overall accuracy.
The much larger (compared with the conventional ITV) MR-ITV created with treatment-length cine MRIs that Dr. Godley described earlier might serve as a proof to this. 8 been FDA-approved for lung and can be integrated with real-time MLC-tracking. 35 In addition to these mature technologies, the feasibility of other real-time lung-tumor monitoring has also been demonstrated with radiation-dose-free Compton-scatter imaging using the therapy beam 37 and with PET emission guidance. 38 In summary, MR-linacs should be better used where they are needed. For lung SBRT, competing technologies are highly successful, and offer higher cost-effectiveness and better solutions. 
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